FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, immunology and medicine. Application of antibody binding to IL-13 is disclosed as medicinal agent for treating asthma in humans. Wherein patient has high expression levels of POSTN in relation to average or median level of POSTN expression. Method of treating asthma subtype using such antibodies is also described.
EFFECT: disclosed group of inventions can be used in medicine.
23 cl, 49 dwg, 13 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | 2019 |
|
RU2795180C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| METHOD FOR DIAGNOSING MOLECULAR PHENOTYPE OF PATIENTS SUFFERING FROM DISEASES ACCOMPANIED BY CHRONIC INFLAMMATION | 2013 |
|
RU2672595C2 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHOD OF TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS | 2006 |
|
RU2419450C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
